Last update 08 May 2025

HER2 x MAGEA1 x TERT

Basic Info

Related Targets
HER2MAGEA1TERT

Related

1
Drugs associated with HER2 x MAGEA1 x TERT
Vx-006
Target
HER2 x MAGEA1 x TERT
Mechanism
HER2 antagonists [+2]
Active Org.
VAXON Biotech SAVAXON Biotech SA
Originator Org.
VAXON Biotech SAVAXON Biotech SA
Active Indication
Neoplasms
Inactive Indication
Solid tumor
Drug Highest PhasePhase 2
First Approval Ctry. / Loc.-
First Approval Date20 Jan 1800
1
Clinical Trials associated with HER2 x MAGEA1 x TERT
NCT02289196
/ CompletedPhase 1
A Multicenter, Open Label, Uncontrolled Phase I Trial to Compare Safety, Tolerability and Immunogenicity of Vx-006 Vaccine at 0.5mg, 1mg, 5mg and 10mg Doses in Human Leukocyte Antigen-A02 (HLA-A02) Positive Patients With Solid Tumours
100 Clinical Results associated with HER2 x MAGEA1 x TERT
Login to view more data
100 Translational Medicine associated with HER2 x MAGEA1 x TERT
Login to view more data
0 Patents (Medical) associated with HER2 x MAGEA1 x TERT
Login to view more data

Analysis

Perform a panoramic analysis of this field.
login
or
view full example data
Perform a panoramic analysis of this field.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free